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Abstract: Metastatic breast cancer is considered an incurable disease. Targeted treatments against the
human epidermal growth factor receptor 2 (HER2), however, significantly improve survival in patients
with metastatic HER2-positive breast cancer. Some patients may respond with prolonged complete
remission. Evidence on safety of long-term trastuzumab and risk of relapse after trastuzumab cessation
is limited. We present a case of an 81-year-old patient with HER2-amplified metastatic breast cancer
(MBC) in the liver. Following taxane-based chemotherapy in combination with trastuzumab after local
treatment resulted in a complete radiological remission after 21 months of trastuzumab maintenance
therapy. The patient remains in complete remission 6 years later and continues to receive trastuzumab
as maintenance therapy. Prolonged remission in cases with complete response under trastuzumab-based
regimens for metastatic HER2-positive breast cancer can be observed in some patients. Reviewing the few
available cases published in the literature, these patients share some common characteristics: hormone
receptor negative disease and metastases to the liver. There is no evidence that trastuzumab maintenance
treatment can be safely interrupted after a certain time period.
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